<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152591</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066X2205</org_study_id>
    <secondary_id>2017-001373-16</secondary_id>
    <nct_id>NCT03152591</nct_id>
  </id_info>
  <brief_title>Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome</brief_title>
  <acronym>PCOS</acronym>
  <official_title>A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate whether LIK066 can be developed for the treatment of
      polycystic ovary syndrome (PCOS) in overweight and obese women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2017</start_date>
  <completion_date type="Actual">June 25, 2018</completion_date>
  <primary_completion_date type="Actual">June 25, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Average Morning Fasting Free Testosterone Blood Concentrations From Baseline</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Luteinizing Hormone (LH) at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Follicle Stimulating Hormone (FSH) at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sex Hormone Binding Globulin (SHBG) at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Androstenedione at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dehydroepiandrostenedione (DHEA) at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dehydroepiandrostenedione Sulfate (DHEAS) at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Testosterone, at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Free Androgen Index (FAI), at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Free Androgen Index (FAI) is a ratio used to determine abnormal androgen status in humans. The ratio is the total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by 100. FAI has no units.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>LIK066</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <description>LIK066 tablets for oral administration</description>
    <arm_group_label>LIK066</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matching LIK066 tablets, for oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  PCOS (diagnosed as clinical or biochemical hyperandrogenism, amenorrhea or
             oligomenorrhea and exclusion of other causes of hyperandrogenism.

          -  Overweight/obese female subjects with BMI of 28 - 45 kg/m^2, inclusive, and stable
             weight +/- 3 kg over previous 3 months

          -  Subjects must use non-hormonal methods of contraception during the study.

        Key Exclusion Criteria:

          -  Subjects with exogenous causes of hirsutism

          -  Menstruation in the 30 days prior to screening or treatment

          -  Pregnant or nursing (lactating) women

          -  Use of prohibited medications

          -  Preexisting medical condition which may significantly alter the absorption,
             metabolism, or excretion of the study drug, or which may jeopardize the subject in
             case of participation in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <results_first_submitted>March 28, 2019</results_first_submitted>
  <results_first_submitted_qc>May 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2019</results_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>PCOS</keyword>
  <keyword>hyperandrogenism</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>overweight</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03152591/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03152591/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in 5 centers in 2 countries: Germany (3), and USA (2).</recruitment_details>
      <pre_assignment_details>Participants were randomized in the ratio of 1:1 to receive either LIK066 50 mg tid or placebo for 14 days and morning dose on Day 15.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LIK066</title>
          <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic (PK) Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacodynamic (PD) Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LIK066</title>
          <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="4.76"/>
                    <measurement group_id="B2" value="29.1" spread="5.66"/>
                    <measurement group_id="B3" value="27.6" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average fasting total testosterone</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.98" spread="0.841"/>
                    <measurement group_id="B2" value="2.07" spread="0.608"/>
                    <measurement group_id="B3" value="2.02" spread="0.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average fasting free testosterone</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.037" spread="0.0163"/>
                    <measurement group_id="B2" value="0.032" spread="0.0086"/>
                    <measurement group_id="B3" value="0.034" spread="0.0132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex hormone binding globulin (SHBG)</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.3" spread="7.72"/>
                    <measurement group_id="B2" value="24.6" spread="10.51"/>
                    <measurement group_id="B3" value="21.4" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Free androgen Index</title>
          <description>Free Androgen Index (FAI) is a ratio used to determine abnormal androgen status in humans. The ratio is the total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by 100. FAI has no units.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" spread="6.65"/>
                    <measurement group_id="B2" value="9.0" spread="2.77"/>
                    <measurement group_id="B3" value="10.7" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Average Morning Fasting Free Testosterone Blood Concentrations From Baseline</title>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Pharmacodynamic (PD) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066</title>
            <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Morning Fasting Free Testosterone Blood Concentrations From Baseline</title>
          <population>Pharmacodynamic (PD) analysis set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" lower_limit="0.77" upper_limit="1.07"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.88" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.353</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Two-sided test at the 0.1 significance level</method_desc>
            <param_type>Ratio LIK066/Placebo</param_type>
            <param_value>0.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <other_analysis_desc>Log transformed ratio of Day 15 to baseline in average fasting free testosterone was analyzed using an analysis of covariance model which included treatment as a categorical factor, baseline body weight and log transformed baseline average fasting free testosterone as a covariate.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Luteinizing Hormone (LH) at Day 15</title>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Pharmacodynamic (PD) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066</title>
            <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Luteinizing Hormone (LH) at Day 15</title>
          <population>Pharmacodynamic (PD) analysis set</population>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="1.11" upper_limit="1.69"/>
                    <measurement group_id="O2" value="1.10" lower_limit="0.89" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.218</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Two-sided test at the 0.1 significance level</method_desc>
            <param_type>Ratio LIK066/Placebo</param_type>
            <param_value>1.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
            <other_analysis_desc>Log transformed ratio of Day 15 to baseline was analyzed using an analysis of covariance model which will include treatment as a categorical factor and log transformed baseline as a covariate.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Follicle Stimulating Hormone (FSH) at Day 15</title>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Pharmacodynamic (PD) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066</title>
            <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Follicle Stimulating Hormone (FSH) at Day 15</title>
          <population>Pharmacodynamic (PD) analysis set</population>
          <units>U/L</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.89" upper_limit="1.43"/>
                    <measurement group_id="O2" value="0.89" lower_limit="0.70" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.249</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Two-sided test at the 0.1 significance level</method_desc>
            <param_type>Ratio LIK066/Placebo</param_type>
            <param_value>1.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
            <other_analysis_desc>Log transformed ratio of Day 15 to baseline was analyzed using an analysis of covariance model which will include treatment as a categorical factor and log transformed baseline as a covariate.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sex Hormone Binding Globulin (SHBG) at Day 15</title>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Pharmacodynamic (PD) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066</title>
            <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sex Hormone Binding Globulin (SHBG) at Day 15</title>
          <population>Pharmacodynamic (PD) analysis set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.95" upper_limit="1.20"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.83" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.173</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Two-sided test at the 0.1 significance level</method_desc>
            <param_type>Ratio LIK066/Placebo</param_type>
            <param_value>1.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
            <estimate_desc>Values &lt; LLOQ and values &gt; ULOQ are imputed as LLOQ/2 and ULOQ respectively.</estimate_desc>
            <other_analysis_desc>Log transformed ratio of Day 15 to baseline was analyzed using an analysis of covariance model which will include treatment as a categorical factor and log transformed baseline as a covariate.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Androstenedione at Day 15</title>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Pharmacodynamic (PD) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066</title>
            <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Androstenedione at Day 15</title>
          <population>Pharmacodynamic (PD) analysis set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.74" upper_limit="0.97"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.91" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.089</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Two-sided test at the 0.1 significance level</method_desc>
            <param_type>Ratio LIK066/Placebo</param_type>
            <param_value>0.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>Values &lt; LLOQ and values &gt; ULOQ are imputed as LLOQ/2 and ULOQ respectively</estimate_desc>
            <other_analysis_desc>Log transformed ratio of Day 15 to baseline was analyzed using an analysis of covariance model which will include treatment as a categorical factor and log transformed baseline as a covariate.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dehydroepiandrostenedione (DHEA) at Day 15</title>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Pharmacodynamic (PD) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066</title>
            <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dehydroepiandrostenedione (DHEA) at Day 15</title>
          <population>Pharmacodynamic (PD) analysis set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.58" upper_limit="0.98"/>
                    <measurement group_id="O2" value="1.09" lower_limit="0.85" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Two-sided test at the 0.1 significance level</method_desc>
            <param_type>Ration LIK066/Placebo</param_type>
            <param_value>0.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Values &lt; LLOQ and values &gt; ULOQ are imputed as LLOQ/2 and ULOQ respectively.</estimate_desc>
            <other_analysis_desc>Log transformed ratio of Day 15 to baseline was analyzed using an analysis of covariance model which will include treatment as a categorical factor and log transformed baseline as a covariate.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dehydroepiandrostenedione Sulfate (DHEAS) at Day 15</title>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Pharmacodynamic (PD) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066</title>
            <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dehydroepiandrostenedione Sulfate (DHEAS) at Day 15</title>
          <population>Pharmacodynamic (PD) analysis set</population>
          <units>umol/L</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" lower_limit="0.75" upper_limit="0.94"/>
                    <measurement group_id="O2" value="1.10" lower_limit="0.99" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Two-sided test at the 0.1 significance level</method_desc>
            <param_type>Ration LIK066/Placebo</param_type>
            <param_value>0.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
            <estimate_desc>Values &lt; LLOQ and values &gt; ULOQ are imputed as LLOQ/2 and ULOQ respectively.</estimate_desc>
            <other_analysis_desc>Log transformed ratio of Day 15 to baseline was analyzed using an analysis of covariance model which will include treatment as a categorical factor and log transformed baseline as a covariate.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Testosterone, at Day 15</title>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Pharmacodynamic (PD) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066</title>
            <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Testosterone, at Day 15</title>
          <population>Pharmacodynamic (PD) analysis set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.84" upper_limit="1.06"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.92" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.340</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Two-sided test at the 0.1 significance level</method_desc>
            <param_type>Ratio LIK066/Placebo</param_type>
            <param_value>0.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <other_analysis_desc>Log transformed ratio of Day 15 to baseline was analyzed using an analysis of covariance model which will include treatment as a categorical factor and log transformed baseline as a covariate.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Free Androgen Index (FAI), at Day 15</title>
        <description>Free Androgen Index (FAI) is a ratio used to determine abnormal androgen status in humans. The ratio is the total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by 100. FAI has no units.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>Pharmacodynamic (PD) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066</title>
            <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Free Androgen Index (FAI), at Day 15</title>
          <description>Free Androgen Index (FAI) is a ratio used to determine abnormal androgen status in humans. The ratio is the total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by 100. FAI has no units.</description>
          <population>Pharmacodynamic (PD) analysis set</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.69" upper_limit="1.05"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.88" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.204</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Two-sided test at the 0.1 significance level</method_desc>
            <param_type>Ratio LIK066/Placebo</param_type>
            <param_value>0.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Values &lt; LLOQ and values &gt; ULOQ are imputed as LLOQ/2 and ULOQ respectively.</estimate_desc>
            <other_analysis_desc>Log transformed ratio of Day 15 to baseline was analyzed using an analysis of covariance model which will include treatment as a categorical factor and log transformed baseline as a covariate.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected for the maximum duration of participants' treatment exposure plus any follow up period, approximately 2 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LIK066</title>
          <description>LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TRACT IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>THIRST</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>VAGINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL MYCOTIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>MENSTRUATION NORMAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>MOOD ALTERED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>POLYURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOMENORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>MENSTRUAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DRY THROAT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

